Home / Market News / $CNTB
benzinga Corporate Catalyst Impact 95/100 ● positive

Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy

Sep 30, 2026, 6:27 PM UTC · Primary ticker $CNTB

Connect Biopharma announced highly positive topline results from its Phase 2 study of rademikibart for COPD, demonstrating an 81% reduction in treatment failure and 100% reduction in hospital admissions/ED visits. This strong clinical data represents a major positive catalyst for the company, significantly de-risking the drug's development and boosting its commercial potential.

Connect Biopharma reported exceptionally strong Phase 2 results for its COPD therapy, rademikibart, showing an 81% reduction in treatment failure and eliminating hospital admissions/ED visits. This data is highly significant as it indicates a potentially transformative treatment for COPD patients with type 2 inflammation, a large and underserved market. For traders, this de-risks the drug's development pathway, suggesting a higher probability of success in later-stage trials and eventual market approval. The immediate impact is a substantial positive re-rating of CNTB shares, reflecting increased investor confidence in the drug's commercial prospects and the company's future growth.

$CNTB positive Strong Phase 2 clinical trial results
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.